Shares in Global Blood Ther­a­peu­tics more than dou­ble on mar­ket de­but

The China Post - - WORLD BUSINESS -

Blood dis­or­der drug devel­oper Global Blood Ther­a­peu­tics’ shares more than dou­bled Wed­nes­day as the com­pany be­came the latest biotech­nol­ogy com­pany to get a pow­er­ful re­sponse from in­vestors in its stock mar­ket de­but.

Global Blood Ther­a­peu­tics Inc. says its treat­ment for sickle cell dis­ease might stop red blood cells from be­com­ing mis­shapen, treat­ing the dis­ease rather than its symp­toms. The drug, GBT440, is in early clin­i­cal test­ing: as of July 31, it had been given to 30 healthy vol­un­teers and six peo­ple with sickle cell dis­ease. The com­pany wants to be­gin at least one mid­stage trial of the drug in early 2016.

Newspapers in English

Newspapers from Taiwan

© PressReader. All rights reserved.